- Home
- WAY vs DNLI Comparison
WAY vs DNLI Comparison
Compare WAY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAY
- DNLI
- Stock Information
- Founded
- WAY 1999
- DNLI 2013
- Country
- WAY United States
- DNLI United States
- Employees
- WAY N/A
- DNLI N/A
- Industry
- WAY
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WAY
- DNLI Health Care
- Exchange
- WAY Nasdaq
- DNLI Nasdaq
- Market Cap
- WAY 4.6B
- DNLI 4.5B
- IPO Year
- WAY 2024
- DNLI 2017
- Fundamental
- Price
- WAY $30.30
- DNLI $25.05
- Analyst Decision
- WAY Strong Buy
- DNLI Strong Buy
- Analyst Count
- WAY 10
- DNLI 11
- Target Price
- WAY $32.11
- DNLI $38.90
- AVG Volume (30 Days)
- WAY 955.0K
- DNLI 788.0K
- Earning Date
- WAY 11-06-2024
- DNLI 11-06-2024
- Dividend Yield
- WAY N/A
- DNLI N/A
- EPS Growth
- WAY N/A
- DNLI N/A
- EPS
- WAY N/A
- DNLI N/A
- Revenue
- WAY $906,142,000.00
- DNLI N/A
- Revenue This Year
- WAY $18.13
- DNLI N/A
- Revenue Next Year
- WAY $8.09
- DNLI $283.75
- P/E Ratio
- WAY N/A
- DNLI N/A
- Revenue Growth
- WAY 18.23
- DNLI 204.74
- 52 Week Low
- WAY $20.26
- DNLI $14.56
- 52 Week High
- WAY $33.25
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- WAY N/A
- DNLI 37.93
- Support Level
- WAY N/A
- DNLI $26.17
- Resistance Level
- WAY N/A
- DNLI $33.33
- Average True Range (ATR)
- WAY 0.00
- DNLI 1.64
- MACD
- WAY 0.00
- DNLI -0.13
- Stochastic Oscillator
- WAY 0.00
- DNLI 0.66
About WAY Waystar Holding Corp. Common Stock
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other US Territories.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.